Company
Celcuity
Nasdaq: CELC
Minneapolis, Minnesota biotech, Nasdaq-listed since 2017. REVTORPYK (gedatolisib), FDA-approved July 2026, is its first and only marketed product — a first-in-class pan-PI3K/mTOR inhibitor for PIK3CA-wild-type HR-positive, HER2-negative advanced breast cancer.
1 story
Regulatory News has published 1 story about Celcuity on 2 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 2 October 2026.
This page is generated from Regulatory News’ editorial coverage of Celcuity. It is not an advertisement.
On the record
- Company
- Celcuity, Inc. (Nasdaq: CELC)
- Headquarters
- Minneapolis, Minnesota
- Founded
- 2012; Nasdaq-listed since 2017
- Regulator
- U.S. Food and Drug Administration (FDA)
- Latest milestone
- First U.S. commercial shipments of REVTORPYK (gedatolisib)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
